BioSpace News Archive

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103) injection: an innovative, humanized, long-acting recombinant glucagon-like peptide-1 (hGLP-1) fused with a hybrid Fc (hyFc) for type 2 diabetes treatment

Modulus Discovery, Inc., an early stage drug discovery company announced today that it has successfully raised a total of 800M Japanese Yen (approximately US $7.2M) for its series A round

New patent protects improvements in oral drug delivery

“Predictors of Opioid-Free Analgesia for Management of Acute Post-Surgical Pain in the U.S.” Finds Patients Most Likely to Receive Opioid-Free Analgesia Were Older or Had Neurological Disorders, Diabetes or Psychosis

2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15, 2018 at 10:55 a.m. Eastern Time.

This fund supports technology programs and services that benefit children and adults, including veterans, living with disabilities.

SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019

GAAP Net Revenue of $414 Million; Adjusted Net Revenue of $462 Million on a Combined Company Basis

PAVmed Inc. announced that the Company will report second quarter financial results on or before August 14, 2018 and host a conference call on Wednesday, August 22, 2018 at 4:30 p.m. Eastern time.

Neptune Technologies & Bioressources Inc. has filed two applications with the United States Patent and Trademark Office (USPTO) for patents related to the extraction of cannabis material.